The fourth COVID-19 vaccine option was authorized July 19 for ages 18 and up. Eligibility grew Aug. 22 to include anyone 12 and older after a phase 3 trial found a 78.3 percent efficacy rate among teenagers when the delta variant was dominant, according to Novavax.
The latecomer’s COVID-19 vaccine is based on technology older than mRNA-based vaccines like Pfizer’s and Moderna’s, which could entice those more comfortable with ingredients used in whooping cough and flu vaccines. As of Aug. 17, though, only 2.1 percent of the nation’s supply of Novavax’s vaccine has been administered, according to CDC data.
Novavax is currently seeking federal authorization for its COVID-19 booster candidate.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.